Generic Name and Formulations:
Antihemophilic Factor VIII (recombinant), porcine sequence 500 Units; per vial; lyophilized pwd for IV inj after reconstitution.
Shire US, Inc.
Indications for OBIZUR:
Treatment of bleeding episodes in acquired Hemophilia A.
Limitations Of use:
Not established in baseline anti-porcine Factor VIII inhibitor titer >20 Bethesda Units (BU). Not for treatment of congenital Hemophilia A or von Willebrand disease.
Individualize. Give by IV inj at rate of 1–2mL/min. Minor and moderate bleed: initially 200 Units/kg every 4–12hrs; titrate subsequent doses to maintain 50–100 Units/dL. Major bleed: initially 200 Units/kg every 4–12hrs; titrate subsequent doses to maintain 100–200 Units/dL (to treat acute bleed) or 50–100 Units/dL (after acute bleed is controlled, if required). Adjust based on FVIII recovery levels and clinical response.
Hamster protein sensitivity.
Monitor for development of inhibitory antibodies; consider other therapies if suspected. Perform a Nijmegen Bethesda inhibitor assay if expected plasma FVIII levels not attained or if bleeding uncontrolled with expected dose. Monitor FVIII activity 30 mins and 3hrs after initial dose, then 30 mins after subsequent doses using one-stage clotting assay. Monitor replacement therapy in major surgery or life-threatening bleeding episodes. Pregnancy (Cat.C). Nursing mothers.
Porcine factor VIII inhibitor development; hypersensitivity reactions (discontinue if occur).
Single-use vials—1, 5, 10 (w. diluent + vial adapter)
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|